Effect of Vitamin A and Calcium in Patients With Non-alcoholic Fatty Liver Disease
NCT06031532 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110
Last updated 2023-09-11
Summary
Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease at a global scale and is strongly associated with the obesity and metabolic syndrome . It is recognized as a hepatic manifestation of the metabolic syndrome, and characterized by lipid infiltration in the hepatocytes. NAFLD comprises a range of diseases from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and may progress to hepatocellular carcinoma (HCC) .
The worldwide prevalence of NAFLD is estimated to be 24% while it is reported to have much higher incidence in patients with metabolic syndrome and type 2 diabetes (T2D) (5). The mortality rate and the number of liver transplantations owing to NAFLD and NASH are increasing, making it the second leading cause of liver transplant in the United States .
Tow significant metabolic abnormalities commonly linked to NAFLD are insulin resistance (IR) and increased supply of fatty acids to the liver . Chronic liver diseases (CLD), including NAFLD, are commonly associated with nutrient and vitamins deficiencies such as those of vitamins D and A (8,9).
Almost all studies documenting vitamin A status in metabolic syndrome (MetS) report reductions in serum retinol, retinoic acid, and/or β-carotene that are inversely correlated with MetS features, including obesity, insulin resistance, glucose intolerance, and hypertriglyceridemia . In line with these observations, inadequate serum retinol levels (\<1.05 μmol/L) were found in 11-36% of morbidly obese adults with ultrasonography-proven NAFLD, and a significant association between low retinol levels and insulin resistance (IR) was found . Moreover, serum retinol levels were inversely associated with body mass and serum transaminases in patients with NAFLD, suggesting a link between retinol inadequacy and development of disease.
The liver plays a critical role in lipid metabolism by taking up serum free fatty acids (FFA) that are involved in the synthesis, storage, and transport of lipid metabolites. The accumulation of excess triacylglycerol (TG) within the liver due to the entry of excess FFA from the obese adipose tissue due to increased lipolysis leads to the development of non-alcoholic fatty liver diseases (NAFLD) .
Conditions
- Effect of Vitamin A and Calcium in Patients With Non-alcoholic Fatty Liver Patients
Sponsors & Collaborators
-
Sohag University
lead OTHER
Eligibility
- Min Age
- 20 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-05-01
- Primary Completion
- 2023-08-01
- Completion
- 2023-08-01
Countries
- Egypt
Study Locations
More Related Trials
-
Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E
NCT01792115 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients
NCT04977661 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Vitamin E on Non-Alcoholic Fatty Liver Disease
NCT02690792 ·Status: COMPLETED ·Phase: NA
-
Impact Of Choline in Patients With NAFLD
NCT05200156 ·Status: UNKNOWN ·Phase: NA
-
Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT04073368 ·Status: COMPLETED ·Phase: NA
-
Dietary Allowance of Methyl Donor Nutrients to Minimize Risks of Non-alcoholic Fatty Liver Progression
NCT05291104 ·Status: COMPLETED ·Phase: NA
-
Rutin and Vitamin C in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
NCT07310407 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Hepatoprotective Measures for Children at High Risk of NAFLD
NCT06918080 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases
NCT04475276 ·Status: COMPLETED ·Phase: PHASE4
-
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
NCT06133101 ·Status: RECRUITING ·Phase: PHASE2
-
Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency
NCT04147936 ·Status: COMPLETED ·Phase: NA
-
Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
NCT00655018 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy of Phosphatidylcholine in NAFLD
NCT04411862 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)
NCT00885313 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Comparison of Effectiveness of Obeticholic Acid With Vitamin E in Patients of Non-alcoholic Fatty Liver Disease
NCT07104786 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of a Probiotic on Hepatic Steatosis
NCT00099723 ·Status: TERMINATED ·Phase: PHASE1
-
Study of the Safety and Tolerability of AXA1957 in Adolescent Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT04073407 ·Status: TERMINATED ·Phase: NA
-
The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver
NCT01956825 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers
NCT03513523 ·Status: COMPLETED ·Phase: NA
-
Coenzyme Q10 and Meclofenoxate in Hepatic Encephalopathy
NCT03961087 ·Status: UNKNOWN ·Phase: NA
-
Vitamin E Dosing Study
NCT04801849 ·Status: COMPLETED ·Phase: PHASE2
-
Polyunsaturated Fatty Acids in Patients With NAFLD.
NCT02647294 ·Status: COMPLETED ·Phase: NA
-
A Feasibility Trial of OCM Supplements for the Treatment of NAFLD
NCT05720702 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease
NCT07285135 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
NCT01934777 ·Status: COMPLETED ·Phase: PHASE3